Clinical trial

A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting

Name

0359-09-FB

Description

This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.

Trial arms

Trial start

2010-10-01

Estimated PCD

2011-09-01

Trial end

2011-09-01

Status

Withdrawn

Treatment

aprepitant

Emend 40mg by mouth 30 minutes before procedure x 1

Arms:

EMEND Added to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting

Other names:

EMEND

Primary endpoint

EMEND Added to Standard Treatment of Post-operative and Post-Discharge Nausea and Vomiting

1 year

Eligibility criteria

Inclusion Criteria: * patients with at least 2 of the common risk factors for PONV/PDNV; patients having a procedure deemed at high risk for PONV/PDNV Exclusion Criteria: * patients under 19 years of age; pregnant and breast-feeding patients

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

Updated at

2023-08-14

1 organization

1 product

1 indication

Organization

University of Nebraska

Product

aprepitant

Indication

Postoperative Nausea and Vomiting